Opioid Use Disorder

Core Idea

Opioid Use Disorder involves chronic use with physiological dependence, tolerance, and compulsive use despite harms. It reflects profound dysregulation of reward and pain systems with significant overdose risk.

Explainer

From your foundation in substance use disorders, you know that all addictive substances share a common pathway: they amplify dopamine signaling in mesolimbic reward circuits. Opioids are especially instructive because they reveal how the brain's own pain and pleasure systems are inseparably linked — and how powerfully they can be hijacked.

The body produces its own opioid peptides — endorphins, enkephalins, and dynorphins — that bind to mu, kappa, and delta opioid receptors throughout the brain and body. These endogenous opioids modulate pain, regulate stress responses, and contribute to the rewarding feelings from exercise, food, and social bonding. Exogenous opioids (heroin, fentanyl, oxycodone) bind the same receptors with far greater potency and reliability. In the ventral tegmental area, mu-opioid receptor activation suppresses inhibitory interneurons, disinhibiting dopamine neurons and producing a large dopamine surge in the nucleus accumbens. Simultaneously, opioids act on brainstem circuits to produce physical pain relief and euphoric sedation — a combination of effects that natural rewards never produce simultaneously or at this magnitude.

With repeated use, the brain adapts through receptor downregulation and desensitization — fewer opioid receptors are expressed and those remaining are less responsive. This is the cellular basis of tolerance: ever-higher doses are needed to achieve the same effect. The body's own opioid system, now chronically suppressed, becomes dependent on exogenous supply. When opioids are removed, the compensatory adaptations are unmasked as withdrawal: pain hypersensitivity, anxiety, insomnia, gastrointestinal distress, and intense craving. This is not weakness — it is the predictable consequence of a biological system that has recalibrated around drug presence.

The overdose risk distinguishes opioid use disorder from most other addictions in lethality. Opioid receptors in the brainstem regulate respiratory drive; overdose causes respiratory depression — breathing slows and stops. Tolerance develops at different rates for different opioid effects: euphoria and sedation develop tolerance quickly, but respiratory depression tolerance develops more slowly and is quickly lost during abstinence. This mismatch kills: a person who has been abstinent for weeks, even months, and returns to their prior dose can fatally overdose because their respiratory depression sensitivity has partially reset while their habitual dose has not. Naloxone — a mu-opioid receptor antagonist — reverses overdose by competitively displacing opioids from receptors, restoring breathing. Medication-assisted treatment with buprenorphine (a partial mu agonist) or methadone (a full agonist with long half-life) works by maintaining partial receptor activation that prevents withdrawal and craving without the peaks and troughs that drive compulsive use.